糖尿病防治新进展.ppt

DISCUSSION Glucagon-like peptide 1 (GLP-1) slowed gastric emptying by 30 to 45 minutes, compared with placebo. This difference was statistically significant through 120 minutes. From 150 minutes through 4 hours, the emptying rate was not significantly different between GLP-1 and placebo. Gastric emptying was near-complete at 150 and 180 minutes following GLP-1 and placebo, respectively. BACKGROUND After a single subcutaneous injection of a high dose of GLP-1 (1.5 nmol/kg) or placebo, gastric content volume was measured every 30 minutes for 4 hours following ingestion of a liquid meal (a premixed amino acid solution) supplied via nasogastric tube Glucose, insulin, C-peptide, GLP-1, and glucagon were also measured Gastric emptying was assessed by a double-sampling dye dilution technique using phenol red As a result of the GLP-1 injection, the integrated incremental glucose response to the liquid meal was reduced by 40% (p=.05) DISCUSSION Glucagon-like peptide 1 (GLP-1) treatment for 6 weeks produced a significant increase in sensations of fullness and satiety and a significant decrease in sensations of hunger and prospective food intake Changes in mean scores from Week 0 to Week 6 within the GLP-1-treated patient group were statistically significant for decreased sensation of hunger (p=.02), increased feeling of fullness (p=.008), and decreased prospective food intake (p=.007); and were statistically significant for increased feeling of satiety at Week 1 only, compared with Week 0 (p=.03) BACKGROUND This study investigated the long-term effects of continuous GLP-1 administration 20 patients (n=10 placebo; n=10 GLP-1) with type 2 diabetes received a 6-week continuous infusion via insulin pump This placebo-controlled proof of concept study demonstrated that GLP-1 administration via continuous subcutaneous infusion had effects on glycaemic control, body weight, insulin resistance, and beta-cell function in a group of patients with type 2 diabetes Several assessment